The clinical symptoms of multiple sclerosis – paralysis and vision disorders – stem from misled immune responses against the cell sheath insulating the nerve fibers. First clues to the mechanisms underlying such destructive “autoimmune“ reactions are described by Privatdozent Dr. Bruno Kyewski, Division of Cellular Immunology of the Deutsches Krebsforschungszentrum, and Dr. Ludger Klein, Dana Faber Cancer Institute, Boston, together with their collaboration partners, in the latest issue of the science journal Nature Medicine*.
As a model system for investigating the molecular causes of this reaction scientists use a disease comparable to multiple sclerosis: experimental autoimmune encephalomyelitis (EAE). EAE can be triggered in certain inbred strains of mice by injecting specific proteins extracted from nerve cells. Among the targets of the self-destructive immune attacks in EAE is a protein called PLP, which is an important component of the insulating sheath of the nerves.
The researchers have studied the production of PLP in the thymus, an organ where immune cells learn to distinguish between “self“ and “nonself“. Immune cells directed against the body’s own structures are sorted out here to prevent them from doing harm. Cells that have passed through this “school“ of the immune system are tolerant of all those self proteins which they have encountered here. However, as the immunologists from Heidelberg have discovered, PLP is produced in the thymus in a shortened version, lacking 35 building blocks of the protein.
Now, what distinguishes EAE-susceptible mice from others not developing this autoimmune reaction? Due to their genetic constitution, EAE-resistant animals do not mount an immune response against the 35 PLP building blocks missing in the thymus. Immune cells attacking other regions of the protein are eliminated anyway. In contrast, in the EAE-susceptible strain scientists have found numerous immune cells targeting exactly the region of the PLP protein which is not produced by the thymus tissue. As the cells do not encounter this target structure in the thymus, the tolerance mechanism fails: They escape elimination and, on their patrols through the body, can cause disastrous damage to the nerve fibers.
According to the authors, a similar mechanism could explain why some people are afflicted by multiple sclerosis. Since only a short variant of PLP is produced in the human thymus, too, our immune system likely cannot acquire complete tolerance for this protein either.
*Klein, L., Klugmann, M., Nave, K.-A., Tuohy, V.K. & Kyewski, B. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nature Medicine, 6:56 (2000)
About DKFZ
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.
To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:
- National Center for Tumor Diseases (NCT, 6 sites)
- German Cancer Consortium (DKTK, 8 sites)
- Hopp Children's Cancer Center (KiTZ) Heidelberg
- Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
- DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
- National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.